Pfizer completes part of Celebrex and Bextra settlement
This article was originally published in Scrip
Executive Summary
Pfizerhas completed part of a larger $894 million US settlement surrounding claims for its two COX-2 inhibitors, Celebrex (celecoxib) and Bextra (valdecoxib), that it announced in October (Scrip Online, October 20th, 2008). The settled claims are with 33 state attorney generals who alleged that the company improperly marketed the two pain products, including "off-label" promotion of Bextra.